Altimmune (ALT) Change in Account Payables (2010 - 2026)
Altimmune (ALT) reported Change in Account Payables of -$1.2 million for Q1 2026, down 237.07% year-over-year from $866000.0 in Q1 2025, and up 43.12% on a QoQ basis from -$2.1 million in Q4 2025.
Altimmune (ALT) has 17 years of Change in Account Payables data on file, last reported at -$1.2 million in Q1 2026.
- Quarterly Change in Account Payables fell 237.07% year-over-year to -$1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $453000.0 (up 116.88% YoY) and the FY2025 annual result came in at $2.5 million, up 234.8% from the prior year.
- Change in Account Payables improved to -$1.2 million in Q1 2026 per ALT's latest filing, from -$2.1 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $4.0 million in Q3 2025 and bottomed at -$2.1 million in Q4 2025.
- The 5-year median for Change in Account Payables is -$922000.0 (2024), against an average of -$29647.1.
- The widest annual swing landed in 2023, when Change in Account Payables tumbled 280.36%; it then jumped 354.21% in 2025.
- Tracing ALT's Change in Account Payables over 5 years: stood at $3.4 million in 2022, then tumbled by 128.83% to -$976000.0 in 2023, then advanced by 5.53% to -$922000.0 in 2024, then sank by 126.36% to -$2.1 million in 2025, then surged by 43.12% to -$1.2 million in 2026.
- Per Business Quant, the three latest ALT Change in Account Payables figures stand at -$1.2 million (Q1 2026), -$2.1 million (Q4 2025), and $4.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -3.26 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 35.60 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Altimmune | 379.61 Mn | 379.61 Mn | - | -1.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.19 Mn |
| Mar 31, 2026 | -1.19 Mn |
| Dec 31, 2025 | -2.09 Mn |
| Dec 31, 2025 | -2.09 Mn |
| Sep 30, 2025 | 3.95 Mn |
| Sep 30, 2025 | 3.95 Mn |
| Jun 30, 2025 | -226,000.00 |
| Jun 30, 2025 | -226,000.00 |
| Mar 31, 2025 | 866,000.00 |
| Mar 31, 2025 | 866,000.00 |
| Dec 31, 2024 | -922,000.00 |
| Dec 31, 2024 | -922,000.00 |
| Sep 30, 2024 | -1.56 Mn |
| Sep 30, 2024 | -1.56 Mn |
| Jun 30, 2024 | -1.07 Mn |
| Jun 30, 2024 | -1.07 Mn |
| Mar 31, 2024 | 1.69 Mn |
| Mar 31, 2024 | 1.69 Mn |
| Dec 31, 2023 | -976,000.00 |
| Dec 31, 2023 | -976,000.00 |
| Sep 30, 2023 | -989,000.00 |
| Sep 30, 2023 | -989,000.00 |
| Jun 30, 2023 | -1.20 Mn |
| Jun 30, 2023 | -1.20 Mn |
| Mar 31, 2023 | 434,000.00 |
| Mar 31, 2023 | 434,000.00 |
| Dec 31, 2022 | 3.39 Mn |
| Dec 31, 2022 | 3.39 Mn |
| Sep 30, 2022 | -1.45 Mn |
| Sep 30, 2022 | -1.45 Mn |
| Jun 30, 2022 | 667,000.00 |
| Jun 30, 2022 | 667,000.00 |
| Mar 31, 2022 | 171,000.00 |
| Mar 31, 2022 | 171,000.00 |
| Dec 31, 2021 | 2.03 Mn |
| Dec 31, 2021 | 2.03 Mn |
| Sep 30, 2021 | -1.42 Mn |
| Sep 30, 2021 | -1.42 Mn |
| Jun 30, 2021 | 1.00 Mn |
| Jun 30, 2021 | 1.00 Mn |
| Mar 31, 2021 | -194,000.00 |
| Mar 31, 2021 | -194,000.00 |
| Dec 31, 2020 | -262,593.00 |
| Dec 31, 2020 | -262,593.00 |
| Sep 30, 2020 | 679,668.00 |
| Sep 30, 2020 | 679,668.00 |
| Jun 30, 2020 | -734,412.00 |
| Jun 30, 2020 | -734,412.00 |
| Mar 31, 2020 | 911,397.00 |
| Mar 31, 2020 | 911,397.00 |
| Dec 31, 2019 | -31,652.00 |
| Dec 31, 2019 | -31,652.00 |
| Sep 30, 2019 | -220,213.00 |
| Sep 30, 2019 | -220,213.00 |
| Jun 30, 2019 | 255,344.00 |
| Jun 30, 2019 | 255,344.00 |
| Mar 31, 2019 | -358,107.00 |
| Mar 31, 2019 | -358,107.00 |
| Dec 31, 2018 | 222,122.00 |
| Dec 31, 2018 | 222,122.00 |
| Sep 30, 2018 | -94,512.00 |
| Sep 30, 2018 | -94,512.00 |
| Jun 30, 2018 | -260,895.00 |
| Jun 30, 2018 | -260,895.00 |
| Mar 31, 2018 | 376,347.00 |
| Mar 31, 2018 | 376,347.00 |
| Dec 31, 2017 | -350,499.00 |
| Dec 31, 2017 | -350,499.00 |
| Sep 30, 2017 | -645,920.00 |
| Sep 30, 2017 | -645,920.00 |
| Jun 30, 2017 | -3.19 Mn |
| Jun 30, 2017 | -3.19 Mn |
| Mar 31, 2017 | 1.57 Mn |
| Mar 31, 2017 | 1.57 Mn |
| Dec 31, 2016 | -71,778.00 |
| Dec 31, 2016 | -71,778.00 |
| Sep 30, 2016 | 802,746.00 |
| Sep 30, 2016 | 802,746.00 |
| Jun 30, 2016 | 477,683.00 |
| Jun 30, 2016 | 477,683.00 |
| Mar 31, 2016 | -354,765.00 |
| Mar 31, 2016 | -354,765.00 |
| Dec 31, 2015 | 214,901.00 |
| Dec 31, 2015 | 214,901.00 |
| Sep 30, 2015 | 97,765.00 |
| Sep 30, 2015 | 97,765.00 |
| Jun 30, 2015 | -329,680.00 |
| Jun 30, 2015 | -329,680.00 |
| Mar 31, 2015 | 146,740.00 |
| Mar 31, 2015 | 146,740.00 |
| Dec 31, 2014 | 109,314.00 |
| Dec 31, 2014 | 109,314.00 |
| Sep 30, 2014 | -155,300.00 |
| Sep 30, 2014 | -155,300.00 |
| Jun 30, 2014 | -34,417.00 |
| Jun 30, 2014 | -34,417.00 |
| Mar 31, 2014 | -656,373.00 |
| Mar 31, 2014 | -656,373.00 |
| Dec 31, 2013 | 18,966.00 |
| Dec 31, 2013 | 18,966.00 |
| Sep 30, 2013 | -1.88 Mn |
| Sep 30, 2013 | -1.88 Mn |
| Jun 30, 2013 | 1.70 Mn |
| Jun 30, 2013 | 1.70 Mn |
| Mar 31, 2013 | -407,653.00 |
| Mar 31, 2013 | -407,653.00 |
| Dec 31, 2012 | -149,203.00 |
| Dec 31, 2012 | -149,203.00 |
| Sep 30, 2012 | -216,250.00 |
| Sep 30, 2012 | -216,250.00 |
| Jun 30, 2012 | 652,294.00 |
| Jun 30, 2012 | 652,294.00 |
| Mar 31, 2012 | -35,280.00 |
| Mar 31, 2012 | -35,280.00 |
| Dec 31, 2011 | 1.00 Mn |
| Dec 31, 2011 | 1.00 Mn |
| Sep 30, 2011 | -2.01 Mn |
| Sep 30, 2011 | -2.01 Mn |
| Jun 30, 2011 | -1.42 Mn |
| Jun 30, 2011 | -1.42 Mn |
| Mar 31, 2011 | 745,895.00 |
| Mar 31, 2011 | 745,895.00 |
| Dec 31, 2010 | -3.57 Mn |
| Dec 31, 2010 | -3.57 Mn |
| Sep 30, 2010 | -1.81 Mn |
| Sep 30, 2010 | -1.81 Mn |